hkasld-hcc-surveillance-expert-pre-meeting-survey

Pre-meeting survey

Please complete the following survey to help support the discussion at the upcoming meeting. Note that there will be the opportunity to expand on your responses during the meeting discussion.

Q1. Approximately how many patients with chronic liver disease do you order alpha-fetoprotein (AFP) assay for hepatocellular carcinoma (HCC) surveillance per month? *

Q2. Approximately how many of your patients have their ultrasound reports available with AFP results for HCC surveillance evaluation? *

Q3. How beneficial is it to conduct biomarker testing, such as the protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein-L3 tests, for the following groups of patients for HCC surveillance? *

a) Hepatitis B virus (HBV) patients without cirrhosis *

1 (Not beneficial)	2	3	4	5 (Highly beneficial)
1 (Not beneficial)a) Hepatitis B virus (HBV) patients without cirrhosis 1 (Not beneficial)	2a) Hepatitis B virus (HBV) patients without cirrhosis 2	3a) Hepatitis B virus (HBV) patients without cirrhosis 3	4a) Hepatitis B virus (HBV) patients without cirrhosis 4	5 (Highly beneficial)a) Hepatitis B virus (HBV) patients without cirrhosis 5 (Highly beneficial)

b) HBV patients with cirrhosis *

1 (Not beneficial)	2	3	4	5 (Highly beneficial)
1 (Not beneficial)a) Hepatitis B virus (HBV) patients without cirrhosis 1 (Not beneficial)	2a) Hepatitis B virus (HBV) patients without cirrhosis 2	3a) Hepatitis B virus (HBV) patients without cirrhosis 3	4a) Hepatitis B virus (HBV) patients without cirrhosis 4	5 (Highly beneficial)a) Hepatitis B virus (HBV) patients without cirrhosis 5 (Highly beneficial)

c) Non-HBV, especially non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) patients without cirrhosis *

1 (Not beneficial)	2	3	4	5 (Highly beneficial)
1 (Not beneficial)a) Hepatitis B virus (HBV) patients without cirrhosis 1 (Not beneficial)	2a) Hepatitis B virus (HBV) patients without cirrhosis 2	3a) Hepatitis B virus (HBV) patients without cirrhosis 3	4a) Hepatitis B virus (HBV) patients without cirrhosis 4	5 (Highly beneficial)a) Hepatitis B virus (HBV) patients without cirrhosis 5 (Highly beneficial)

d) Non-HBV patients with cirrhosis *

1 (Not beneficial)	2	3	4	5 (Highly beneficial)
1 (Not beneficial)a) Hepatitis B virus (HBV) patients without cirrhosis 1 (Not beneficial)	2a) Hepatitis B virus (HBV) patients without cirrhosis 2	3a) Hepatitis B virus (HBV) patients without cirrhosis 3	4a) Hepatitis B virus (HBV) patients without cirrhosis 4	5 (Highly beneficial)a) Hepatitis B virus (HBV) patients without cirrhosis 5 (Highly beneficial)

Q4. The value of the PIVKA-II test in HCC surveillance is to: *

a) …complement AFP testing and ultrasound for early HCC detection *

1 (Not useful)	2	3	4	5 (Very useful)
1 (Not useful)a) …complement AFP testing and ultrasound for early HCC detection 1 (Not useful)	2a) …complement AFP testing and ultrasound for early HCC detection 2	3a) …complement AFP testing and ultrasound for early HCC detection 3	4a) …complement AFP testing and ultrasound for early HCC detection 4	5 (Very useful)a) …complement AFP testing and ultrasound for early HCC detection 5 (Very useful)

b) …partly replace ultrasound in routine HCC surveillance *

1 (Not useful)	2	3	4	5 (Very useful)
1 (Not useful)a) …complement AFP testing and ultrasound for early HCC detection 1 (Not useful)	2a) …complement AFP testing and ultrasound for early HCC detection 2	3a) …complement AFP testing and ultrasound for early HCC detection 3	4a) …complement AFP testing and ultrasound for early HCC detection 4	5 (Very useful)a) …complement AFP testing and ultrasound for early HCC detection 5 (Very useful)

c) …detect HCC in patients with chronic liver inflammation and positive AFP results *

1 (Not useful)	2	3	4	5 (Very useful)
1 (Not useful)a) …complement AFP testing and ultrasound for early HCC detection 1 (Not useful)	2a) …complement AFP testing and ultrasound for early HCC detection 2	3a) …complement AFP testing and ultrasound for early HCC detection 3	4a) …complement AFP testing and ultrasound for early HCC detection 4	5 (Very useful)a) …complement AFP testing and ultrasound for early HCC detection 5 (Very useful)

d) …complement imaging and AFP evaluation for HCC recurrent detection among patients with curative treatment of HCC *

1 (Not useful)	2	3	4	5 (Very useful)
1 (Not useful)a) …complement AFP testing and ultrasound for early HCC detection 1 (Not useful)	2a) …complement AFP testing and ultrasound for early HCC detection 2	3a) …complement AFP testing and ultrasound for early HCC detection 3	4a) …complement AFP testing and ultrasound for early HCC detection 4	5 (Very useful)a) …complement AFP testing and ultrasound for early HCC detection 5 (Very useful)